Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase-1 first-in-human, single-center, randomized, double-blind, placebo-controlled, sponsor-unblinded study to determine safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating oral doses of INCB000928 in healthy adult participants

Next Previous
Trial Profile

A phase-1 first-in-human, single-center, randomized, double-blind, placebo-controlled, sponsor-unblinded study to determine safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating oral doses of INCB000928 in healthy adult participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zilurgisertib (Primary)
  • Indications Anaemia; Fibrodysplasia ossificans progressiva; Myelofibrosis
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics

Most Recent Events

  • 07 Nov 2022 New trial record
  • 27 Sep 2022 Results presented at the 2022 American College of Clinical Pharmacology Annual Meeting

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top